Education
About Us
Working with TipRanks
Follow Us
Day One Biopharmaceuticals (DAWN)
NASDAQ:DAWN
DAWN Stock Chart & Stats
$10.16
-$0.14(-1.13%)
At close: 4:00 PM EST
$10.16
-$0.14(-1.13%)
Day’s Range― - ―
52-Week Range$5.64 - $13.53
Previous CloseN/A
Volume175.11K
Average Volume (3M)2.70M
Market Cap
$1.07B
Enterprise Value$688.45M
Total Cash (Recent Filing)$451.58M
Total Debt (Recent Filing)$2.89M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Mar 09, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding105,704,636
10 Day Avg. Volume2,984,986
30 Day Avg. Volume2,696,127
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.36
Price to Sales (P/S)9.04
P/FCF Ratio-14.78
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue5.15
Enterprise Value/Gross Profit5.76
Enterprise Value/Ebitda-4.86
Forecast
1Y Price Target
$23.71Price Target Upside133.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.54
Revenue Forecast (FY)$231.49M
Bulls Say, Bears Say
Bulls Say
Commercial AdoptionExpanding new patient starts and strong prescription growth, together with about 90% of on‑label patients receiving approval on first request, support continued commercial uptake of Ojemda.
Durable Clinical Benefit And Re-treatmentRe-treatment after a drug holiday produced strong tumor shrinkage and extended treatment‑free periods, indicating durable benefit and reducing concerns about rapid resistance that could encourage broader prescribing.
Pipeline Clinical OpportunitiesEarly clinical data from DAY301 and forthcoming antibody‑drug conjugate programs could open development across multiple tumor types, providing meaningful pipeline optionality beyond current indications.
Bears Say
Development And Regulatory UncertaintyUncertainty about timing of additional dosing data, futility assessments, and regulatory interactions for the Emi‑Le program increases development risk and could delay progress toward potential approvals.
Physician Prescribing HesitancySome clinicians remain hesitant to prescribe Ojemda for certain patient groups, which could limit market penetration despite available clinical evidence.
Safety Profile — Growth SuppressionA significant share of patients experienced marked slowing of growth, including severe decreases in growth velocity, which may remain a barrier for clinician and caregiver acceptance.
Day One Biopharmaceuticals News
DAWN FAQ
What was Day One Biopharmaceuticals’s price range in the past 12 months?
Day One Biopharmaceuticals lowest stock price was $5.63 and its highest was $13.53 in the past 12 months.
What is Day One Biopharmaceuticals’s market cap?
Day One Biopharmaceuticals’s market cap is $1.07B.
When is Day One Biopharmaceuticals’s upcoming earnings report date?
Day One Biopharmaceuticals’s upcoming earnings report date is Mar 09, 2026 which is in 49 days.
How were Day One Biopharmaceuticals’s earnings last quarter?
Day One Biopharmaceuticals released its earnings results on Nov 04, 2025. The company reported -$0.19 earnings per share for the quarter, beating the consensus estimate of -$0.297 by $0.107.
Is Day One Biopharmaceuticals overvalued?
According to Wall Street analysts Day One Biopharmaceuticals’s price is currently Undervalued.
Does Day One Biopharmaceuticals pay dividends?
Day One Biopharmaceuticals does not currently pay dividends.
What is Day One Biopharmaceuticals’s EPS estimate?
Day One Biopharmaceuticals’s EPS estimate is -0.19.
How many shares outstanding does Day One Biopharmaceuticals have?
Day One Biopharmaceuticals has 105,704,636 shares outstanding.
What happened to Day One Biopharmaceuticals’s price movement after its last earnings report?
Day One Biopharmaceuticals reported an EPS of -$0.19 in its last earnings report, beating expectations of -$0.297. Following the earnings report the stock price went up 25.205%.
Which hedge fund is a major shareholder of Day One Biopharmaceuticals?
Currently, no hedge funds are holding shares in DAWN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Day One Biopharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.71 (133.37% Upside)
$23.71 (133.37% Upside)
Blogger Sentiment
Bullish
DAWN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 878.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.6%
Last 30 Days ▲ 56.3%
Last 30 Days ▲ 56.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.06%
12-Months-Change
Fundamentals
Return on Equity
-30.16%
Trailing 12-Months
Asset Growth
-14.49%
Trailing 12-Months
Company Description
Day One Biopharmaceuticals
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
DAWN Company Deck
DAWN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a positive outlook with strong revenue growth, increased prescriptions, and positive clinical data. The raised revenue guidance and inclusion in NCCN guidelines further support a positive trajectory. However, the high gross-to-net ratio and limited impact of EAP patients were noted challenges.View all DAWN earnings summariesDAWN Stock 12 Month Forecast
Average Price Target
$23.71
▲(133.37% Upside)
Technical Analysis
Theravance Biopharma
―
Kura Oncology
―
Gossamer Bio
―
Maravai Lifesciences Holdings
―
Septerna, Inc.
―
Ownership Overview
1.60% Insiders
17.81% Mutual Funds
0.36% Other Institutional Investors
67.65% Public Companies and
Individual Investors